Guangzhou LBP Medicine Science & Technology Co Ltd
688393
Company Profile
Business description
Guangzhou LBP Medicine Science & Technology Co Ltd is engaged in production and sales of in vitro diagnostic reagents and instruments. The company's products include Fluorescence in situ hybridization (FISH) series; Immunohistochemistry (IHC) series; Liquid - based cytology (LBP) series; PCR series; and medical laboratory.
Contact
Building 7, No. 11, Nanxiang 3rd Road
Guangzhou High-tech Industrial Development Zone
Guangdong Province
Guangzhou510663
CHNT: +86 2032299997
Sector
Healthcare
Stock type
Defensive
Industry
Medical Instruments & Supplies
Fiscal Year End
31 December 2026
Employees
796
Stocks News & Analysis
stocks
Chart of the Week: Inflation fears dampen sentiment on retailers
Rising inflation is the fly in the ointment.
stocks
Here’s 3 Top Rated ASX shares for 2026
As we start the new year, let’s take a closer look at three compelling opportunities on the ASX
stocks
Undervalued Aussie e-commerce winner
Shares attractive due to near term profit margin increase and structural growth.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,046.50 | 7.00 | 0.08% |
| CAC 40 | 8,233.92 | 3.51 | -0.04% |
| DAX 40 | 25,122.26 | 230.06 | 0.92% |
| Dow JONES (US) | 48,996.08 | 466.00 | -0.94% |
| FTSE 100 | 10,048.21 | 74.52 | -0.74% |
| HKSE | 26,080.57 | 629.88 | -2.36% |
| NASDAQ | 23,584.28 | 37.10 | 0.16% |
| Nikkei 225 | 51,323.26 | 1,194.82 | -2.28% |
| NZX 50 Index | 13,716.86 | 1.84 | 0.01% |
| S&P 500 | 6,920.93 | 23.89 | -0.34% |
| S&P/ASX 200 | 8,720.80 | 2.70 | -0.03% |
| SSE Composite Index | 4,083.73 | 2.04 | -0.05% |